AAX Biotech announces new collaboration for high-resolution epitope mapping in clinical antibody development
Biotech company AAX Biotech, specializing in innovative technologies for improving antibody-based medicines, is pleased to announce a new collaboration focused on developing antibody-based therapies for acute and critical care of cardiovascular disease. By applying its high-resolution epitope mapping technology, AAX Biotech will support the development of clinical-stage antibodies to strengthen regulatory submissions and optimize its clinical advancement.
AAX Biotech is dedicated to advancing next-generation antibody therapeutics by developing innovative technologies that address key challenges in biopharmaceutical development. By focusing on high-resolution epitope mapping and antibody engineering, the company delivers advanced solutions that enhance antibody performance and support clinical success.
The partner is advancing their drug candidate through clinical trials, where precise epitope mapping is essential for regulatory approval and optimizing therapeutic potential. By delivering detailed molecular insights, it helps refine antibody specificity, minimize off-target effects, and guide clinical decision-making.
Using its proprietary Seqitope® technology, AAX Biotech will conduct advanced epitope mapping of the humanized monoclonal antibody currently in clinical development as well as related antibodies. Seqitope® sets a new standard in accuracy and depth compared to traditional approaches, delivering essential data to improve antibody design and therapeutic potential.
"We are pleased to support our partner in this important phase of their drug candidate’s clinical development," says Maria L. Knudsen, CEO of AAX Biotech. "With Seqitope®, we provide the precision needed to optimize antibody characterization, and we look forward to supporting their continued progress."
For more information, please contact:
Maria Lisa Knudsen, CEO
+46 72 939 5018
maria.knudsen@aaxbiotech.com
About AAX Biotech AB
AAX Biotech AB is a biotech company specializing in next-generation antibody therapeutics. The company offers two unique and proprietary technologies, Seqitope® and Opti-mAb™, that enable high throughput and high-resolution epitope mapping as well as stabilization of single chain variable fragments (scFv) for applications such as bispecific antibodies and CAR-T cells. Both technologies aim to produce better and more effective antibody-based medicines. These innovations position AAX Biotech as a key player in the rapidly growing antibody therapeutics market. AAX Biotech is founded by experts from Karolinska Institutet in Stockholm, Sweden. Visit aaxbiotech.com to learn more and follow AAX Biotech on LinkedIn.
